drugset
drugset / Trial / NCT04384523

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

NCT04384523 ↗

Phase 1 Completed 41 enrolled Healthgen Biotechnology Corp.
RandomizedSequentialDouble-blindOther

Summary

A Phase 1 randomized, double blinded, placebo-controlled single dose escalation study of OsrHSA in adult healthy male and female volunteers

Timeline

Start
2019-11-04
Primary completion
2020-03-17
Completion
2020-07-13

Drugs

EvaluationDrugModalityDoseRoute
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 20 mg/kg Intravenous
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 40 mg/kg Intravenous
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 80 mg/kg Intravenous
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 140 mg/kg Intravenous
Subject HUMAN SERUM ALBUMIN, RECOMBINANT RICE-DERIVED Protein / enzyme biologic 200 mg/kg Intravenous

Indications

No indication recorded.